Skip to content
HowShorted

CytomX Therapeutics, Inc. short interest in 2021

In 2021, CytomX Therapeutics, Inc.'s disclosed short interest ran from 6.52% of shares outstanding on 15 Jan 2021 to 4.74% on 31 Dec 2021, a change of -1.78 percentage points. The year's high was 10.74% on 30 Jul 2021 and its low 4.74% on 31 Dec 2021, averaging 8.13% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.67 days on 15 Oct 2021. Full history: CytomX Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CytomX Therapeutics, Inc. in 2021

2021 in figures

Start of year
6.52% (15 Jan 2021)
End of year
4.74% (31 Dec 2021)
Change
-1.78 pp
High
10.74% (30 Jul 2021)
Low
4.74% (31 Dec 2021)
Average
8.13%
Highest days to cover
14.67 (15 Oct 2021)
SEC filings marked
9

Every report in 2021

CytomX Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20216.52%8.17
29 Jan 20217.87%1.84results (8-K)
12 Feb 20215.13%3.59
26 Feb 20215.13%5.3010-K filed, results (8-K)
15 Mar 20216.05%6.23
31 Mar 20219.90%6.22
15 Apr 20219.55%7.23
30 Apr 202110.25%8.49
14 May 202110.35%5.2210-Q filed, results (8-K)
28 May 202110.21%12.59
15 Jun 202110.27%9.67
30 Jun 202110.21%6.48
15 Jul 202110.23%9.21
30 Jul 202110.74%13.29
13 Aug 202110.25%8.2510-Q filed, results (8-K)
31 Aug 20219.05%9.34
15 Sep 20218.04%9.66
30 Sep 20217.46%7.53
15 Oct 20216.91%14.67
29 Oct 20217.43%8.85
15 Nov 20217.17%5.2810-Q filed, results (8-K)
30 Nov 20215.61%3.46
15 Dec 20216.12%3.72
31 Dec 20214.74%1.03

See also: CytomX Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.